Kåre Schultz: Lundbeck is in for a record year

Denmark's Lundbeck is in for the best year in the company’s history, according to CEO Kåre Schultz who kicked off the year with a guidance hike and revenue of more than USD 150 million. “We do not need any mysteries or miracles. We just need to stay focused,” he says.

Adm. direktør for Lundbeck

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us for 14 days

Try a trial subscription for access to our quality journalism

Frontpage right now

FDA vil lette vejen til markedet for medicin mod Alzheimers

De amerikanske lægemiddelmyndigheder vil lempe kravene til godkendelse af lægemidler mod Alzheimers, fordi forskning viser, at sygdommen indtræder tidligere end hidtil antaget. Lægemiddeludviklingen og godkendelse heraf derfor skal tilpasses derefter, mener FDA-boss Scott Gottlieb.

Related articles